Assessing minimal or measurable residual disease is continuing to become an important strategy in the management of patients with various hematological malignancies, including acute lymphoblastic and acute myeloblastic, acute myeloid leukemia. And of course there are different assays, including flow cytometry, as well as molecular analysis.
So, for example, in the case of NPM1 mutated AML this has been shown that persistence of NPM1 clones after two cycles of chemotherapy is highly associated with a higher risk of relapse and adverse outcome...
Assessing minimal or measurable residual disease is continuing to become an important strategy in the management of patients with various hematological malignancies, including acute lymphoblastic and acute myeloblastic, acute myeloid leukemia. And of course there are different assays, including flow cytometry, as well as molecular analysis.
So, for example, in the case of NPM1 mutated AML this has been shown that persistence of NPM1 clones after two cycles of chemotherapy is highly associated with a higher risk of relapse and adverse outcome.
Of course, I believe that we can actually combine these strategies, both flow cytometry and molecular analysis, to increase the predictability of an MRD-negative state. It has been shown, in some studies, that if you have two assays that are negative, this is likely to be more associated with a lower risk of relapse, as opposed to if both assays are positive or at least one of the assays are positive. So, I think perhaps the future will really depend, to at least some degree, on the combination of these strategies to assess for persistent MRD.